Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932289 · ClinicalTrials.gov registry record · NA
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
A NA study, sponsored by VA Greater Los Angeles Healthcare System.
- Not yet
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT06932289: Clinical Trial NA study, sponsored by VA Greater Los Angeles Healthcare System.
NCT06932289 is a NA study that has not yet begun recruiting, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06932289, a NA study, has not yet begun recruiting, sponsored by VA Greater Los Angeles Healthcare System.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
Primary Outcome
The concentration of glucose (mg/dL) will be measured during each visit, across the different diets, to evaluate changes in metabolism
Interventions
- DIETARY_SUPPLEMENT Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF)
- DEVICE The integrated sweat sensor and vascular sensor (wearable)
- DEVICE continuous glucose monitor (CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2029-05-01 |
| Phase | NA |
What is known before NCT06932289 opens enrollment
NCT06932289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF) is the first listed.
NCT06932289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06932289 about?
NCT06932289 is a clinical study titled "Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions". It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
What is the current status of trial NCT06932289?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-05-01. Estimated completion is 2029-05-01.
What interventions are being tested in trial NCT06932289?
The interventions under investigation include: Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF) (DIETARY_SUPPLEMENT), The integrated sweat sensor and vascular sensor (wearable) (DEVICE), continuous glucose monitor (CGM) (DEVICE).
Who is sponsoring clinical trial NCT06932289?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06932289's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI